REBECCA monitoring of prostate cancer patients 

At Stavanger University Hospital (SUH) in Norway, efforts are focused on monitoring the quality of life of cancer patients affected by cancer-related fatigue (CRF) after primary treatment. In traditional clinical trials, patients’ quality of life and CRF status are typically assessed using questionnaires, known as Patient-Reported Outcome Measures (PROMs). However, these methods rely on subjective patient opinions, leading to significant variability in perceptions of CRF.

To address this limitation, the REBECCA study has adopted a novel approach, using real-world data collected through smartwatches and mobile apps. This method enables real-time, objective monitoring of patients’ quality of life. CRF has a profound impact on daily functioning, often hindering physical activity, social engagement, and work-life participation. By using the REBECCA system, we aim to characterise these challenges and side effects in patients’ everyday lives.

While much attention has been given to CRF in breast cancer patients, men with prostate cancer also frequently experience CRF following primary treatment. To expand our understanding, the third clinical REBECCA study at SUH, called the REBECCA-PROST study or REBECCA-3, focuses on monitoring the quality of life in prostate cancer patients. This study seeks to provide new insights into the side effects experienced by prostate cancer patients post-treatment, potentially improving future follow-up care for this group. Additionally, the study will explore whether the REBECCA system can be extended to other cancer types and patient populations.

Study design

The REBECCA-PROST (REBECCA-3) feasibility study was launched in December 2023. It invites prostate cancer patients who underwent primary surgery or radiation treatment before December 2024, had localised disease, and no previous cancer diagnoses, to participate. Patients are recruited from the Department of Urology, in collaboration with team members at the Department of Hematology and Oncology, SUH.

The study aims to recruit 40 patients. To date, 45 patients have been invited, and 26 have consented to participate. Participants are included at the time of diagnosis and receive the REBECCA system following the completion of primary treatment for four months of digital data collection.

Data collection

In addition to continuous digital data gathered during follow-up, patients complete quality of life questionnaires (PROMs) during three study visits. To uncover the underlying mechanisms of CRF—which remain poorly understood—the study also collects blood and stool samples. These biological samples are analysed at the Department of Pathology, SUH, with the goal of identifying potential biomarkers associated with CRF. As of now, six patients have completed their participation in the study.

We extend our heartfelt gratitude to all participants who have contributed to the REBECCA study for their invaluable effort and support.